CA2524071A1 - Effecteur du recepteur tlr 9 et ses utilisations - Google Patents

Effecteur du recepteur tlr 9 et ses utilisations Download PDF

Info

Publication number
CA2524071A1
CA2524071A1 CA002524071A CA2524071A CA2524071A1 CA 2524071 A1 CA2524071 A1 CA 2524071A1 CA 002524071 A CA002524071 A CA 002524071A CA 2524071 A CA2524071 A CA 2524071A CA 2524071 A1 CA2524071 A1 CA 2524071A1
Authority
CA
Canada
Prior art keywords
tlr9
leu
ser
binding agent
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002524071A
Other languages
English (en)
Inventor
Ashlyn Bassiri
Anuk Das
Susan Dillon
Karen Duffy
Jonathan Seideman
Lars Karlsson
Sun Siquan
Jian Zhu
M. Lamine Mbow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor, Inc.
Ashlyn Bassiri
Anuk Das
Susan Dillon
Karen Duffy
Jonathan Seideman
Lars Karlsson
Sun Siquan
Jian Zhu
M. Lamine Mbow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc., Ashlyn Bassiri, Anuk Das, Susan Dillon, Karen Duffy, Jonathan Seideman, Lars Karlsson, Sun Siquan, Jian Zhu, M. Lamine Mbow filed Critical Centocor, Inc.
Publication of CA2524071A1 publication Critical patent/CA2524071A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002524071A 2003-04-29 2004-04-29 Effecteur du recepteur tlr 9 et ses utilisations Abandoned CA2524071A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46634103P 2003-04-29 2003-04-29
US60/466,341 2003-04-29
PCT/US2004/013816 WO2004096156A2 (fr) 2003-04-29 2004-04-29 Effecteur du recepteur tlr 9 et ses utilisations

Publications (1)

Publication Number Publication Date
CA2524071A1 true CA2524071A1 (fr) 2004-11-11

Family

ID=33418366

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002524071A Abandoned CA2524071A1 (fr) 2003-04-29 2004-04-29 Effecteur du recepteur tlr 9 et ses utilisations

Country Status (3)

Country Link
EP (1) EP1620070A2 (fr)
CA (1) CA2524071A1 (fr)
WO (1) WO2004096156A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131074A1 (fr) 2007-04-19 2008-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Utilisation d'agonistes du récepteur 9 de type toll (tlr9), d'antagonistes du récepteur 4 de type toll (tlr4), et/ou d'agonistes du domaine 2 d'oligomérisation nucléaire (nod2) pour le traitement ou la prévention de troubles associés au récepteur 4 de type toll
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
EP2173912A4 (fr) * 2007-08-01 2013-03-20 Idera Pharmaceuticals Inc Nouveaux agonistes synthétiques de tlr9
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
WO2012088425A2 (fr) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Agents favorisant les jonctions communicantes utilisables en vue du traitement de l'entérocolite nécrosante et des affections intestinales inflammatoires non spécifiques
US9562066B2 (en) 2012-09-25 2017-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
WO2024054992A1 (fr) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Procédés de séparation d'agent chélateur

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002304329A1 (en) * 2001-03-07 2002-09-19 University Of Lausanne Methods for regulation of immune responses to conditions involving mediator-induced pathology

Also Published As

Publication number Publication date
WO2004096156A3 (fr) 2009-04-02
WO2004096156A2 (fr) 2004-11-11
EP1620070A2 (fr) 2006-02-01

Similar Documents

Publication Publication Date Title
US11359020B2 (en) Agents that modulate immune cell activation and methods of use thereof
JP6140777B2 (ja) ヒトｉｌ−６受容体に対する高親和性抗体
JP5677744B2 (ja) ヒトＤｅｌｔａ様リガンド４に対するヒト抗体
JP4754219B2 (ja) 腫瘍壊死因子を対象とする抗体、およびそれらの使用
JP3675819B2 (ja) Ｃｄ４０に対する抗体
JP6027849B2 (ja) Ｉｌ−２１アンタゴニスト
KR20180127971A (ko) 신규 항-pd-l1 항체
KR20090029184A (ko) 항체 조성물 및 신생물성 질병의 치료 방법
KR20200004324A (ko) 인간 항-세마포린 4d 항체
JP2011507495A (ja) 神経再生のモジュレーター
JP2022527506A (ja) Ｃｄ４０活性化特性を有する組換えタンパク質
KR20210131336A (ko) Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
KR20220092584A (ko) 항tigit 항체 및 이의 용도
JP2007525416A (ja) 早期活性化分子のターゲティングに基づく免疫調節
JP2007525416A5 (fr)
CA2524071A1 (fr) Effecteur du recepteur tlr 9 et ses utilisations
KR20230029611A (ko) T 세포를 선택적으로 조절하기 위한 이중특이적 분자
US20050244410A1 (en) Toll-like receptor 9 effector agents and uses thereof
EP3946453A1 (fr) Anticorps anti-axl et leurs méthodes d'utilisation
US20230055411A1 (en) Monoclonal antibody against stim1
CN113660945A (zh) 抗cd55抗体和相关组合物和方法
US20230058212A1 (en) Monoclonal antibody against stim1
JP2011148829A (ja) 早期活性化分子のターゲティングに基づく免疫調節
KR20230020521A (ko) 아고니스트 항-cd40 항체
CN117946265A (zh) 抗cx3cl1抗体及其应用

Legal Events

Date Code Title Description
FZDE Discontinued